Articles from Pharmaceutical Strategies Group

Employers and health plans are actively responding to the challenge of rising specialty drug costs, according to the newly-released 2025 Trends in Specialty Drug Benefits Report from Pharmaceutical Strategies Group (“PSG”), an EPIC company. The report was co-sponsored by Genentech and has been published for 12 years. Based on in-depth survey responses from more than 230 pharmacy benefit leaders, the report provides a comprehensive look at how organizations are managing complex, high-cost therapies and exploring innovative specialty drug management strategies.

The 2024 Pharmacy Benefit Manager Customer Satisfaction Report published by Pharmaceutical Strategies Group (“PSG”) disclosed low satisfaction and demand for change in the industry amongst healthcare payers. The report is the most comprehensive research on pharmaceutical benefit managers (PBMs), with a comprehensive look into the increasingly complex structures and functions of today’s marketplace.

Pharmaceutical Strategies Group (“PSG”), an EPIC company, announces the release of the latest solution on its proprietary Artemetrx® integrated data platform, Artemetrx GeneCQ™.

Pharmaceutical Strategies Group (“PSG”), an EPIC company, releases its proprietary Artemetrx® State of Specialty Spend and Trend report, sponsored by Walmart Specialty Pharmacy. In its eighth year, the report uses integrated pharmacy and medical claims data to provide a holistic view of specialty drug spend and trend. First published in 2017, this report is the sole comprehensive analysis of specialty drug spending, powered by the industry’s leading integrated dataset through Artemetrx.

Pharmaceutical Strategies Group (“PSG”), an EPIC company, released its annual Trends in Drug Benefit Design Report, sponsored by Prescryptive Health, detailing the trends and leading strategies for traditional drug benefits. The research provides valuable insights about drug benefit design and management.

Pharmaceutical Strategies Group (“PSG”), an EPIC company, has added two significant enhancements to its leadership team aimed at further empowering healthcare payers and driving innovation within the pharmacy benefits industry. The company welcomes Mike Sackett as SVP of Financial Analytics, Procurement, and Consulting Strategy and celebrates the well-deserved promotion of Rebekah Gregg to Chief Operating Officer.

Pharmaceutical Strategies Group (“PSG”), an EPIC company, released its annual Trends in Specialty Drug Benefits Report, co-sponsored by Genentech, a member of the Roche Group, detailing the complexities of specialty drug access and affordability. The proprietary research spotlights how employers and health plans are navigating the increasingly complex landscape of specialty drug access for patients.

Satisfaction with pharmacy benefit managers (PBMs) has plunged to its lowest level in nearly a decade, according to Pharmaceutical Strategies Group’s newly-released 2023 Pharmacy Benefit Manager Customer Satisfaction Report.

Pharmaceutical Strategies Group (PSG), an EPIC company, is pleased to announce the release of its proprietary Artemetrx® State of Specialty Spend and Trend report, sponsored by Walmart. The seventh annual report uses integrated pharmacy and medical claims data to provide a holistic view of specialty drug spend and trend. First published in 2017, this report is the sole comprehensive analysis of specialty drug spending, powered by the industry’s leading integrated dataset through Artemetrx.

Pharmaceutical Strategies Group (PSG), an EPIC company, has released its 25th annual 2022 Pharmacy Benefit Manager Customer Satisfaction Report. This extensive report represents the most comprehensive satisfaction research survey in the pharmacy benefit manager (PBM) space, providing unparalleled data and insights.

Pharmaceutical Strategies Group (PSG), an EPIC company, announced an enhancement of its data and analytics platform, Artemetrx®, which will significantly enhance clients’ ability to track and report on the adoption of biosimilar medications. Artemetrx is the leading integrated pharmacy and medical claims platform and is utilized by health plans, pharmacy benefit managers, and employers for drug cost management.

Pharmaceutical Strategies Group (PSG), an EPIC company, has released its highly anticipated Artemetrx® State of Specialty Spend and Trend Report. The sixth-annual report uses integrated pharmacy and medical claims data to formulate a holistic view of specialty spend and trend. Since its inception in 2017, it has served as the only comprehensive analysis of specialty drug spending, powered by the industry’s leading integrated dataset through Artemetrx.

New research on the latest trends in benefit design launches today. Pharmaceutical Strategies Group (PSG), an EPIC company, developed the Trends in Drug Benefit Design Report—sponsored by Rx Savings Solutions. The proprietary research uncovers salient insights into the perceptions and challenges around high deductible health plans (HDHPs), the role of member experience, formulary strategy, and how the Great Resignation and pandemic have shifted plan design priorities.

Extensive research about the latest trends in specialty benefit design launches today. Pharmaceutical Strategies Group (PSG), an EPIC company, developed the Trends in Specialty Benefit Design Report. This proprietary research delivers detailed intelligence to enhance the ability of employers, labor groups, and other plan sponsors to unpack the specialty drug benefit design landscape.

The most comprehensive customer satisfaction report in the PBM space launches today. Pharmaceutical Strategies Group (PSG), an EPIC company, developed the 2021 PBM Customer Satisfaction Report.

Artemetrx Rebate Monitor accelerates health plan ability to identify and resolve variances in pharmacy benefit manager (PBM) rebates. Industry insiders designed the newly unveiled tool to revolutionize the approach to rebate guarantees.

Pharmaceutical Strategies Group (PSG) released the highly anticipated fifth annual State of Specialty Spend and Trend Report. This report uses integrated pharmacy and medical claims data to formulate a holistic view of specialty spend and trend.

The most comprehensive customer satisfaction report in the PBM space launches today. It delivers detailed intelligence to enhance the ability of payers and plan sponsors to manage pharmacy benefits strategically.

Modernized health tech platform, Artemetrx, is now available for the unprecedented transformation of integrated data into meaningful strategies and proactive drug cost management for employers and managed care organizations (MCO).